



ANDA 215393

ANDA APPROVAL

Padagis US, LLC
U.S. Agent for Padagis Israel Pharmaceuticals, Ltd.
Attention: Anna Voght
Regulatory Affairs Manager

Dear Anna Voght:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on January 25, 2021, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Tazarotene Lotion, 0.045%.

Reference is also made to the complete response letter issued by this office on March 21, 2025, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly the ANDA is **approved**, effective on the date of this letter. We have determined your Tazarotene Lotion, 0.045% to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Arazlo Lotion, 0.045%, of Bausch Health US, LLC (Bausch), NDA - 211882.

The RLD upon which you have based your ANDA, Bausch's Arazlo Lotion, 0.045%, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
11,311,482 (the '482 patent)	May 11, 2038
11,679,116 (the '116 patent)	June 6, 2036
12,128,137 (the '137 patent)	May 11, 2038

Your ANDA contains paragraph IV certifications to each of the patents, under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Tazarotene Lotion, 0.045%, under this ANDA. You have notified the Agency that Padagis Israel Pharmaceuticals, Ltd. (Padagis) complied with the requirements of section 505(j)(2)(B) of the FD&C Act.

With respect to 180-day generic drug exclusivity, we note that Padagis was a first ANDA applicant for Tazarotene Lotion, 0.045%, to submit a substantially complete ANDA with a paragraph IV certification. Therefore, with this approval, Padagis may be eligible for 180 days of generic drug exclusivity for Tazarotene Lotion, 0.045%. This exclusivity, which is provided for under 505(j)(5)(B)(iv) of the FD&C Act, would begin to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv). The Agency notes that Padagis failed to obtain tentative approval of this ANDA within 30 months after the date of which the ANDA was filed. See section 505(j)(5)(D)(i)(IV) of the FD&C Act (forfeiture of exclusivity for failure to obtain tentative approval). The Agency is not, however, making a formal determination at this time of Padagis's eligibility for 180-day generic drug exclusivity. We will do so only if a subsequent paragraph IV applicant becomes eligible for full approval (a) within 180 days after Padagis begins commercial marketing of Tazarotene Lotion, 0.045%, or (b) at any time prior to the expiration of the '482 patent if Padagis has not begun commercial marketing. Please submit correspondence to this ANDA notifying the Agency within 30 days of the date of the first commercial marketing of this drug product or the RLD. If you do not notify the Agency within 30 days, the date of first commercial marketing will be deemed to be the date of the drug product's approval. See 21 CFR 314.107(c)(2).

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website as <https://www.uspnf.com/>.

REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others.

For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas>.

Sincerely yours,

{See appended electronic signature page}

For Malik Imam, PharmD, MBA
CDR, United States Public Health Service
Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



Paul
Levine

Digitally signed by Paul Levine

Date: 7/29/2025 09:38:54AM

GUID: 56323ddc003554a87fad6698c2baa467